Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092452 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT04092452 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 194 participants.
The verdict
NCT04092452, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
Interventions
- DRUG Placebo
- DRUG PF-06650833
- DRUG PF-06700841
- DRUG PF-06826647
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04092452
The ClinicalTrials.gov registry entry for NCT04092452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04092452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04092452 about?
NCT04092452 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa". This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
What is the current status of trial NCT04092452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2019-12-02. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT04092452?
The interventions under investigation include: Placebo (DRUG), PF-06650833 (DRUG), PF-06700841 (DRUG), PF-06826647 (DRUG).
Who is sponsoring clinical trial NCT04092452?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.